Full Year 2025 Fresenius Medical Care AG Earnings Call Transcript

Feb 24, 2026 / 01:00PM GMT

Release Date Price: €38.65 (+5.01%)

Transcript

Key Points

Positve

Fresenius Medical Care AG (FMS) achieved the upper end of its 2025 financial outlook, with a significant step up in profitability and an exceptional fourth quarter performance.
The company launched its New 2030 Strategy, FME Reignite, aimed at accelerating growth and driving ambitious profitability improvements.
Fresenius Medical Care AG (FMS) successfully initiated a EUR1 billion share buyback program, reflecting a strengthened financial profile and commitment to returning excess cash to shareholders.
The company achieved sustainable savings above its increased target through the FME25+ savings program, supporting a significant step up in profitability.
Fresenius Medical Care AG (FMS) delivered strong organic revenue growth of 8% and earnings growth of 53% in the fourth quarter, resulting in a margin of 13.9%.

Negative

The company faced unanticipated headwinds from lower volumes and elevated medical benefit costs in 2025.
Regulatory pressure in China negatively impacted Care Enablement revenue development, with stricter tender requirements and delayed tenders expected to impact 2026.
Fresenius Medical Care AG (FMS) anticipates a headwind from the phasing out of phosphate binder and TDAPA contributions in 2026.
The company expects regulatory impacts to affect earnings development by EUR150 million to EUR200 million in 2026.
Fresenius Medical Care AG (FMS) faces challenges in achieving same market treatment growth, with flat growth assumed for 2026 due to ongoing pressures.

Operator

Hello ladies and gentlemen. Welcome to the report on the fourth-quarter and financial year 2025 conference call. I'm Mauritz, the chorus call operator. (Operator Instructions) And the conference is being recorded. (Operator Instructions) The conference must not be recorded for publication or broadcast.

At this time, it's my pleasure to hand over to Dr. Dominik Heger. Please go ahead, sir.

Dominik Heger

Fresenius Medical Care AG - Head of Investor Relations, Strategic Development & Communications, EVP

Thank you, Mauritz. Welcome everyone to our earnings call for the fourth quarter and the financial year 2025. As always, I start out the call by mentioning our cautionary language that is in our Safe Harbor statement, as well as in our presentation and in all the materials that we have distributed earlier today. For further details concerning risks and uncertainties, please refer to these documents and to our SEC filings.

We will have one hour for the call. In order to give everyone the chance to ask questions, we would limit the number of

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.